Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease

2011/07/26 by Marie‐Thérèse Armentero, Marie Therese Armentero, Annalisa Pinna +5 · 1 citation
Biochemistry, Genetics and Molecular Biology · Medicine · Neuroscience · #Adenosine #Adenosine A2A receptor #Adenosine and Purinergic Signaling #Adenosine receptor #Agonist #Basal ganglia #Biology #Central nervous system #Disease #Dopamine #Dopamine receptor D2 #Internal medicine #Medicine #Neurodegeneration #Neuroscience #Parkinson's disease #Pharmacological Receptor Mechanisms and Effects #Pharmacology #Receptor #Receptor Mechanisms and Signaling

paper · doi:10.1016/j.pharmthera.2011.07.004

openalex publication_date 2011/07/26 · crossref created 2011/07/26 · crossref issued 2011/12/01 · crossref published 2011/12/01 · crossref published-print 2011/12/01 · openalex created_date 2016/06/24 · crossref deposited 2025/03/07 · crossref indexed 2026/06/13 · openalex updated_date 2026/08/04

Citations

• Pharmacokinetics and Metabolism of Natural Methylxanthines in Animal and Man
• Xanthines as Adenosine Receptor Antagonists
• Structure of an Agonist-Bound Human A 2A Adenosine Receptor
• 3,7-Dimethyl-1-propargylxanthine: A potent and selective in vivo antagonist of adenosine analogs

Cited by

• Management of Parkinson's disease [wikipedia]